# Mechanism of Response to IMFINZI Neoadjuvant Therapy in Non-small Cell Lung Cancer Patients Based on Multiple-omics Models

> **NCT04646837** · PHASE1,PHASE2 · UNKNOWN · sponsor: **Peking Union Medical College Hospital** · enrollment: 20 (estimated)

## Conditions studied

- Non-small Cell Lung Cancer

## Interventions

- **DRUG:** Durvalumab
- **DRUG:** Albumin Paclitaxel
- **DRUG:** Carboplatin/Cisplatin

## Key facts

- **NCT ID:** NCT04646837
- **Lead sponsor:** Peking Union Medical College Hospital
- **Sponsor class:** OTHER
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2021-05-01
- **Primary completion:** 2024-05-01
- **Final completion:** 2025-03
- **Target enrollment:** 20 (ESTIMATED)
- **Last updated:** 2023-03-29

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04646837

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04646837, "Mechanism of Response to IMFINZI Neoadjuvant Therapy in Non-small Cell Lung Cancer Patients Based on Multiple-omics Models". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT04646837. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*